Congressional subcommittee criticizes NIH for lax conflict of interest policies. NIH Director Zerhouni promises change. The subcommittee has asked several NCI officials to testify at another hearing next week.
Also in this 8-page issue: Intel Chairman Andrew Grove slams NCI director and cancer program for “wishful dreams” and “chemo speeches,” recommends moratorium on funding for cancer research.
Trending Stories
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns









